中国中西医结合皮肤性病学杂志2025，Vol.24Issue(3)：193-198,6.
252例中重度特应性皮炎患者临床治疗模式与达标情况分析
Analysis of Clinical Treatment Mode and Treat-to-target in 252 Patients with Moderate and Severe Atopic Dermatitis
摘要
Abstract
Objective In order to analyze the treatment mode and treat-to-target of integrated traditional Chinese and western medicine for patients with moderate and severe atopic dermatitis(AD)in a hospital,so as to provide references for the clinical treatment mode and strategy of moderate and severe AD patients under the development of new drugs.Methods The clinical data of 252 patients with moderate and severe AD treated by the chronic disease management team of Guangdong hospital of provincial Chinese medicine from June 2020 to December 2023 were retrospectively analyzed.The patients were sorted into traditional Chinese medicine group(n=32),conventional western medicine group(n=2),traditional Chinese medicine combined with western medicine group(n=115),dupilumab combined with traditional Chinese medicine group(n=93),dupilumab combined with conventional western medicine group(n=8)and Janus kinase(JAK)inhibitor group(n=2).The treat-to-target and the occurrence of adverse reactions in each group were analyzed.Results The treat-to-target rates of traditional Chinese medicine group,traditional Chinese medicine combined with conventional western medicine group,dupilumab combined with traditional Chinese medicine group and dupilumab combined with conventional western medicine group were 50.00％,52.17％,90.32％and 87.50％,respectively.The overall differences were statistically significant(P＜0.05).In terms of the proportion of patients whose peak pruritus numerical rating scale(PP-NRS)improvement ≥ 4 points,dermatology life quality index(DLQI)improvement≥4 points and the treat-to-target rates,there was significant difference between the traditional Chinese medicine group and the dupilumab combined with traditional Chinese medicine group,and between the traditional Chinese medicine combined with western medicine group and the dupilumab combined with traditional Chinese medicine group(P＜0.05).In terms of the proportion of patients reaching EASI-75,there were significant differences between the traditional Chinese medicine group and the dupilumab combined with traditional Chinese medicine group,the traditional Chinese medicine group with the dupilumab combined with conventional western medicine group,the traditional Chinese medicine combined with conventional western medicine group and the dupilumab combined with conventional western medicine group(P＜0.05).During the observation period,adverse reactions were reported in four cases(1.59％),which were mild ocular symptoms and could be alleviated by local treatment.Conclusion At present,new drugs such as biological agents have greatly improved the clinical efficacy and safety of patients with moderate and severe AD,and the combination with traditional western medicine or traditional Chinese medicine has gradually become a new therapeutic trend,in which the combination with traditional Chinese medicine is expected to improve the rate of treat-to-target in a short time,and the adverse risk is low,which provides the possibility for further discussion on the stopping and maintenance scheme of western medicine under the mode of combination of traditional Chinese and western medicine.关键词
特应性皮炎/治疗模式/达标治疗/回顾分析Key words
Atopic dermatitis/Treatment mode/Treat-to-target/Retrospective analysis分类
医药卫生引用本文复制引用
杨映柳,王靖雯,周渤钎,王家爵,肖君琳,刘俊峰,叶思祺,张瑜,莫秀梅..252例中重度特应性皮炎患者临床治疗模式与达标情况分析[J].中国中西医结合皮肤性病学杂志,2025,24(3):193-198,6.基金项目
国家中医药管理局开展重大疑难疾病中西医结合诊疗方案的研究(特应性湿疹中西医结合临床实践指南,编号:2023376) （特应性湿疹中西医结合临床实践指南,编号:2023376）
省部共建中医湿证国家重点实验室重点项目(编号:SZ2021ZZ39) （编号:SZ2021ZZ39）
广州市科技计划项目(编号:2023B03J0562、2023A03J0747). （编号:2023B03J0562、2023A03J0747）
